The short version of freeze-thaw fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-10 and is reviewed periodically as new material appears.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
Unlike soil, hydroponic nutrient solutions do not have cation-exchange capacity (CEC) from clay particles or organic matter. The absence of CEC and soil pores means the pH, oxygen saturation, and nutrient concentrations can change much more rapidly in hydroponic setups than is possible in soil. Selective absorption of nutrients by plants often imbalances the amount of counterions in solution. This imbalance can rapidly affect solution pH and the ability of plants to absorb nutrients of similar ionic charge (see article membrane potential). For instance, nitrate anions are often consumed rapidly by plants to form proteins, leaving an excess of cations in solution. This cation imbalance can lead to deficiency symptoms in other cation based nutrients (e.g. Mg2+) even when an ideal quantity of those nutrients are dissolved in the solution. Depending on the pH or on the presence of water contaminants, nutrients such as iron can precipitate from the solution and become unavailable to plants. Routine adjustments to pH, buffering the solution, or the use of chelating agents is often necessary. Unlike soil types, which can vary greatly in their composition, hydroponic solutions are often standardized and require routine maintenance for plant cultivation. Under controlled laboratory conditions hydroponic solutions are periodically pH adjusted to near neutral (pH 6.0) and are aerated with oxygen.
Difficult or impossible to repair or recondition after wear or damage Outgassing and "sweating" of plasticizers and other chemicals from poorly formulated products Typically not as durable as genuine leather
==== MeSH D12.776.210.500.570 – myogenic regulatory factors ==== MeSH D12.776.210.500.570.590 – myod protein MeSH D12.776.210.500.570.595 – myogenic regulatory factor 5 MeSH D12.776.210.500.570.600 – myogenin
Sources: en.wikipedia.org
=== Interactions with Dictyostelium === The slime mold Dictyostelium discoideum contains "farmer" individuals that live in association with Pseudomonas fluorescens. Two strains of the bacterium are associated with the farmer. One strain serves as a food source and the other strain serves as a symbiont that produces beneficial secondary metabolites. The main genetic difference between these two strains is a mutation of the global activator gene called gacA. This gene plays a key role in gene regulation; when this gene is knocked out in the nonfood bacterial strain, it loses its special secondary metabolites and, independently, is transformed into a food strain.
=== Hormonal regulation of insulin secretion === Several hormones can affect insulin secretion. Estrogen is correlated with an increase of insulin secretion by depolarizing the β-cells membrane and enhancing the entry of Ca2+. In contrast, growth hormone is known to lower the serum level of insulin by promoting the production of insulin-like growth factor-I (IGF-I). IGF-I, in turn, suppresses the insulin secretion.
=== Supraventricular tachycardia === In individuals with supraventricular tachycardia (SVT), adenosine is a first line treatment used to help identify and convert the rhythm. Certain SVTs can be successfully terminated with adenosine. This includes any re-entrant arrhythmias that require the AV node for the re-entry, e.g., AV reentrant tachycardia (AVRT) and AV nodal reentrant tachycardia (AVNRT). In addition, atrial tachycardia can sometimes be terminated with adenosine. Fast rhythms of the heart that are confined to the atria (e.g., atrial fibrillation and atrial flutter) or ventricles (e.g., monomorphic ventricular tachycardia), and do not involve the AV node as part of the re-entrant circuit, are not typically converted by adenosine. However, the ventricular response rate is temporarily slowed with adenosine in such cases. Because of the effects of adenosine on AV node-dependent SVTs, adenosine is considered a class V antiarrhythmic agent. When adenosine is used to cardiovert an abnormal rhythm, it is normal for the heart to enter ventricular asystole for a few seconds. This can be disconcerting to a normally conscious patient, and is associated with angina-like sensations in the chest.
== Epidemiology == In most countries, between 1 in 50 and 1 in 200 people have coeliac disease. Rates vary in different regions of the world; coeliac disease is less common in places where gluten-containing crops are rarely eaten, and in parts of east Asia and sub-Saharan Africa where populations rarely carry the HLA-DQ genes that predispose to the disease. The risk of developing coeliac disease is higher in those who have a first-degree relative with the disease; a less dramatic increase in risk is also seen in second-degree relatives. Diagnoses of coeliac disease have increased dramatically in recent decades due to increased awareness of the disease and the availability of blood testing. However, the disease is still thought to be underdiagnosed, with an estimated 70% of people with coeliac disease undiagnosed and untreated. Undiagnosed cases are more common in poorer areas and in countries that do not regularly test at-risk people. While coeliac disease can arise at any age, most people develop the disease before age 10. Roughly 20 percent of individuals with coeliac disease are diagnosed after 60 years of age. Coeliac disease is slightly more common in women than in men, though some of that may be due to differences in diagnostic practice, as men with gastrointestinal symptoms are less likely to receive a biopsy than women.
Sources: en.wikipedia.org
=== Period 3: final narrative evolution === The final stage at Kizil is Period 3 of the Second Indo-Iranian Style. Towards the end of its florescence, Kizil saw the emergence of the domed central pillar cave, a type of "central pillar" structure, with niche and circumambulating corridor, but with a very uncharacteristic near-cubic main cella crowned by a magnificent cupola decorated with divinities. The style of painting is very refined, and can also be seen in some other caves in the region such as in Kumtura. The iconography too has evolved, with a cosmological Buddha becoming omnipresent and majestic, often surrounded by myriads of emanations of smaller Buddhas. This exceptional and very refined type of cave is exemplified by Cave 123, the "Cave with the Ring-Bearing Doves". It represents a final narrative evolution, in which the figures of the cosmological Buddha predominate, while secondary figures and stories take an ever-smaller role.
Two types of atomic bomb were developed by the United States during World War II: a uranium-based device (codenamed "Little Boy") whose fissile material was highly enriched uranium, and a plutonium-based device (see Trinity test and "Fat Man") whose plutonium was derived from uranium-238. Little Boy became the first nuclear weapon used in war when it was detonated over Hiroshima, Japan, on 6 August 1945. Exploding with a yield equivalent to 12,500 tonnes of TNT, the blast and thermal wave of the bomb destroyed nearly 50,000 buildings and killed about 75,000 people (see Atomic bombings of Hiroshima and Nagasaki). In 1943 the Manhattan Project contracted two private companies, Union Carbide and Chevron, to quietly compile a survey of uranium deposits around the world. As the survey results came in, two geology professors studied the results and suggested general guidelines for new sources, including uranium associated with gold mines in the Rand area in South Africa. Initially it was believed that uranium was relatively rare, and that nuclear proliferation could be avoided by simply buying up all known uranium stocks, but within a decade large deposits of it were discovered in many places around the world.
=== Regulatory elements === To build and develop biological systems, regulating components including regulators, ribosome-binding sites (RBSs), and terminators are crucial. Despite years of study, there are many various varieties and numbers of promoters and terminators for Escherichia coli, but also for the well-researched model organism Saccharomyces cerevisiae, as well as for other organisms of interest, these tools are quite scarce. Numerous techniques have been invented for the finding and identification of promoters and terminators in order to overcome this constraint, including genome mining, random mutagenesis, hybrid engineering, biophysical modelling, combinatorial design, and rational design.
John Kampfner, author, broadcaster and commentator; executive director at Chatham House; has written and presented for Reuters, The Daily Telegraph; chief political correspondent at the Financial Times; political commentator for BBC's Today radio programme; political correspondent on Newsnight; was chair of the Clore Duffield Foundation, Council of King's College London; Chief Executive of the freedom of expression organisation Index on Censorship and established Creative Industries Federation; shortlisted for the Orwell Book prize. Efraim Karsh (born 6 September 1953) British-Israeli historian at King's College London; director of political studies Bar-Ilan University the Begin-Sadat Center for Strategic Studies).; former director of Middle East Forum; held posts at Harvard, Columbia universities, Sorbonne, London School of Economics, Helsinki University, International Institute for Strategic Studies, Kennan Institute for Advanced Russian Studies in Washington D.C., and Jaffee Center for Strategic Studies at Tel Aviv University; in 1989 joined King's College London; has contributed articles to The New York Times, The Los Angeles Times, The Wall Street Journal, The Times (London) and The Daily Telegraph. His book Palestine Betrayed argued that 1948 Palestinian expulsion and flight was "exclusively of their own making".
The drug is a controlled substance in many countries, so non-medical use for purposes such as improving physique and performance has been generally illicit. In the United States, the FDA's Endocrinologic and Metabolic Drugs Advisory Committee unanimously concluded in 1984 that there was no evidence of efficacy for oxandrolone. On March 26, 2019, Gemini asked FDA to withdraw approval for all doses of the drug, stating that they were no longer marketing it. FDA notified Gemini and other license holders on December 16, 2022, that it believed that the potential problems with the drug that the drug were sufficiently serious that it should be removed from the market, citing the 1984 finding of lack of efficacy and the extensive safety warnings and precautions listed on the prescribing information, "including peliosis hepatis, sometimes associated with liver failure and intra-abdominal hemorrhage; liver cell tumors, sometimes fatal; and blood lipid changes that are known to be associated with increased risk of atherosclerosis" as well as "cholestatic hepatitis, hypercalcemia in patients with breast cancer, and increased risk for the development of prostatic hypertrophy and prostatic carcinoma in geriatric patients." Gemini and Sandoz requested that the FDA completely withdraw approval for the drug.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.